Michael Gallo

USPTO Granted Patents = 20 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 523(Granted Patents)

Location History:

San Jose, CA (US) (2001 - 2012)
Vancouver, CA (2006 - 2020)

Company Filing History:

Innovative Targeting Solutions Inc.

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10563206 - Generating targeted sequence diversity in fusion proteins (2020-02-18),

2. 10233453 - Generating targeted sequence diversity in fusion proteins (2019-03-19),

3. 9914929 - Generating targeted sequence diversity in fusion proteins (2018-03-13),

4. 9718871 - Generating targeted sequence diversity in proteins (2017-08-01),

5. 9315577 - Anti-hepcidin antibodies and methods of use (2016-04-19),

6. 9234041 - Antibodies to insulin-like growth factor I receptor (2016-01-12),

7. 8642037 - Antibodies to insulin-like growth factor I receptor (2014-02-04),

8. 8617845 - Sequence diversity generation in immunoglobulins (2013-12-31),

9. 8568992 - Antibody categorization based on binding characteristics (2013-10-29),

10. 8227580 - Human monoclonal antibodies to epidermal growth factor receptor (2012-07-24),

11. 8206936 - Antibody categorization based on binding characteristics (2012-06-26),

12. 8012714 - Sequence diversity generation in immunoglobulins (2011-09-06),

13. 7982024 - Antibodies to insulin-like growth factor I receptor (2011-07-19),

14. 7815907 - Antibodies to insulin-like growth factor I receptor (2010-10-19),

15. 7807798 - Human monoclonal antibodies to epidermal growth factor receptor (2010-10-05),

Title: Michael Gallo - Innovator in Fusion Protein Technologies

Introduction

Michael Gallo, based in North Vancouver, Canada, is a prominent inventor recognized for his contributions to the field of biotechnology. With an impressive portfolio of 20 patents, Gallo has made significant strides in developing innovative methods for generating fusion protein variants. His work aims to enhance the functionality of proteins, opening up new possibilities in therapeutic applications.

Latest Patents

One of Gallo's latest patents focuses on generating targeted sequence diversity in fusion proteins. This method introduces sequence diversity at the junction regions within the fusion protein, allowing for the creation of variants that exhibit desired activities. His innovative approach includes the use of polynucleotides that encode these fusion proteins, comprising multiple RSSs, as well as the development of various compositions and host cells that incorporate these proteins. By bridging immunoglobulins with specific domains or polypeptides, Gallo's work promises enhanced performance in therapeutic settings.

Career Highlights

Throughout his career, Gallo has worked with reputable companies such as Amgen and Pfizer Corporation, where he contributed to advancing biotechnological research and applications. His experience in these leading organizations has provided him with the platform to innovate and make a substantial impact in the field of fusion proteins.

Collaborations

Michael Gallo has collaborated with accomplished professionals in the industry, including Jaspal Singh Kang and Xiao-Chi Jia. These collaborations have further enriched the scope of his research, facilitating the development of groundbreaking technologies in protein engineering.

Conclusion

Michael Gallo's contributions to biotechnology, particularly in the arena of fusion proteins, exemplify the impact of innovation on medicine and therapeutics. With a strong foundation of patents and collaborative efforts, he continues to inspire future advancements in this dynamic field.

This text is generated by artificial intelligence and may not be accurate.